Compare Marathon Petroleum Corp (MPC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Pfizer Inc — how do they compare? Marathon Petroleum Corp trades at $461.19 (market cap $130.12B), while Pfizer Inc trades at $28.16 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Pfizer Inc for 158 Days on average.
| MPC | PFE | |
|---|---|---|
Market Cap | $130.12B | $158.56B |
Volume | 2,749,647 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $463.34 | $29.02 |
52-Week Low | $162.63 | $23.67 |
Typical Hold Time | 54 Days | 158 Days |
Enterprise Value | $156.64B | $210.06B |
Dividend Yield | 0.86% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $461.79, up 4.42% today, showing strong momentum with three consecutive earnings beats. Technical indicators signal bullish momentum with the stock trading near resistance at $463. Fundamentally, the company maintains solid profitability with 5.57% net margin and 47.9% ROE, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Analyst consensus remains strongly bullish with 25 buy ratings and a $420.30 price target.
MPC presents a compelling value opportunity with attractive valuation multiples (P/E 16.07, P/S 0.9) and strong earnings momentum. Key risks include potential diesel export restrictions, declining revenue trends, and elevated debt levels. The stock's current price above consensus target suggests near-term caution despite positive technical and fundamental momentum.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
